Literature DB >> 18569903

"Look, I'm fit, I'm positive and I'll be all right, thank you very much": coping with hepatitis C treatment and unrealistic optimism.

Carla Treloar1, Max Hopwood.   

Abstract

Hepatitis C treatment is known to produce significant physical and psychiatric side-effects. Healthcare workers in hepatitis C treatment clinics focus on preparing people to cope with these side-effects. Unrealistic optimism, or judging oneself to be at low risk of negative events, has been implicated in contributing to practices that place health at risk and to delays in seeking help or facilitating coping with negative events. In the context of hepatitis C treatment, patients with overly optimistic expectations of their ability to cope with treatment-related side-effects are less prepared for their impact and therefore may be more likely to discontinue treatment. In this exploratory qualitative study, data from semi-structured interviews with 20 people undergoing hepatitis C treatment and six healthcare workers at three hepatitis C treatment clinics in Sydney, Australia were explored for the presence of unrealistic optimism and also the impact that this had on patients' processing of information pre-treatment and management of side-effects during treatment. The concept of unrealistic optimism was evident in both patients' and healthcare workers' interview transcripts. Patients' descriptions of their preparation for hepatitis C treatment included references to delays in seeking help for depressive symptoms attributable to unrealistic optimism. Healthcare workers also discussed their observations of the effects of unrealistic optimism on patients' coping strategies. Data from this study contribute to an understanding of unrealistic optimism and its impact on the experience of hepatitis C treatment side-effects, patients' coping styles and potential for delays in seeking help. Unrealistic optimism should be explored as part of pre-treatment assessments for hepatitis C treatment and considered throughout treatment to avoid delays in help seeking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569903     DOI: 10.1080/13548500701477532

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  7 in total

Review 1.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.

Authors:  Magdalena Harris; Tim Rhodes
Journal:  Harm Reduct J       Date:  2013-05-07

2.  Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment.

Authors:  Jessica L Zuchowski; Alison B Hamilton; Jeffrey M Pyne; Jack A Clark; Aanand D Naik; Donna L Smith; Fasiha Kanwal
Journal:  BMC Gastroenterol       Date:  2015-10-01       Impact factor: 3.067

3.  How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study.

Authors:  Shu-Mei Tsai; Jung-Ta Kao; Yun-Fang Tsai
Journal:  BMC Health Serv Res       Date:  2016-07-11       Impact factor: 2.655

Review 4.  Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature.

Authors:  Laura E Dowsett; Stephanie Coward; Diane L Lorenzetti; Gail MacKean; Fiona Clement
Journal:  Can J Gastroenterol Hepatol       Date:  2017-04-26

Review 5.  The ongoing impacts of hepatitis c--a systematic narrative review of the literature.

Authors:  Emma R Miller; Stephen McNally; Jack Wallace; Marisa Schlichthorst
Journal:  BMC Public Health       Date:  2012-08-18       Impact factor: 3.295

6.  Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review.

Authors:  Amirhossein Modabbernia; Hossein Poustchi; Reza Malekzadeh
Journal:  Hepat Mon       Date:  2013-01-07       Impact factor: 0.660

7.  Unrealistic Optimism in the Time of Coronavirus Pandemic: May It Help to Kill, If So-Whom: Disease or the Person?

Authors:  Dariusz Dolinski; Barbara Dolinska; Barbara Zmaczynska-Witek; Maciej Banach; Wojciech Kulesza
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.